STING1 and neoplasm: Although certain promising results have been obtained, the application of STING agonists to clinics remains challenging with the potential pro-tumor functions of STING pathway12–15 and the difficulty for achieving a persistent STING activation due to the existence of a negative feedback regulation mediated by protein degradation16,17.